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ABSTRACT
Dysregulated macrophage cholesterol homoeostasis lies at the heart of early and developing
atheroma, and removal of excess cholesterol from macrophage foam cells, by efﬁcient transport
mechanisms, is central to stabilization and regression of atherosclerotic lesions. The present
study demonstrates that transient overexpression of STARD3 {START [StAR (steroidogenic acute
regulatory protein)-related lipid transfer] domain 3; also known as MLN64 (metastatic lymph node
64)}, an endosomal cholesterol transporter and member of the ‘START’ family of lipid trafﬁcking
proteins, induces signiﬁcant increases in macrophage ABCA1 (ATP-binding cassette transporter
A1) mRNA and protein, enhances [3H]cholesterol efﬂux to apo (apolipoprotein) AI, and reduces
biosynthesis of cholesterol, cholesteryl ester, fatty acids, triacylglycerol and phospholipids from
[14C]acetate, compared with controls. Notably, overexpression of STARD3 prevents increases
in cholesterol esteriﬁcation in response to acetylated LDL (low-density lipoprotein), blocking
cholesteryl ester deposition. Thus enhanced endosomal trafﬁcking via STARD3 induces an anti-
atherogenic macrophage lipid phenotype, positing a potentially therapeutic strategy.
INTRODUCTION
Dysregulated macrophage cholesterol homoeostasis lies
at the heart of early and developing atheroma, the
principal cause of coronary heart disease. Macrophage
‘foam cells’, laden with cholesterol and cholesteryl ester,
result from unregulated uptake of modiﬁed lipoproteins
by macrophage scavenger receptors (CD36, CD68 and
SR-AI/AII), and inﬂuence both plaque stability and pro-
gression [1]. Removal of excess cholesterol from
macrophage ‘foam’ cells is central to lesion regression
and stabilization, and can be orchestrated, at least
in vitro, by ABC (ATP-binding cassette) lipid trans-
porters such as ABCA1, ABCG1 and ABCG4, and
apo (apolipoprotein) acceptors, such as apoAI and apoE
[2]. Efﬁcient intracellular cholesterol transport is pivotal
in marshalling appropriate cholesterol homoeostasis
mechanisms, regulating sterol-responsive transcription
factors, such as LXRα/β (liver X receptors α/β)a n d
SREBPs (sterol-regulatory-element-binding proteins),
and controlling cholesterol content of organelles,
lipid rafts and membranes, and storage as cytosolic
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droplets of cholesteryl ester [2,3]. Despite this, the
proteins involved in non-vesicular cholesterol transport
mechanisms remain poorly understood.
The START [StAR (steroidogenic acute regulatory
protein)-related lipid transfer] domain is a 210 amino
acid conserved ‘helix-grip’ fold, providing an adaptable
binding site for lipids such as cholesterol, oxysterols,
phospholipids and ceramides. In humans, START
domains are found in 15 distinct proteins (STARD1–
STARD15), implicated in non-vesicular lipid transport,
cell signalling and lipid metabolism [4,5]. The prototypic
member of this family, StAR (STARD1), delivers
cholesterol from the outer to the inner mitochondrial
membrane, to the CYP (cytochrome P450) side-
chain-cleavage enzyme involved in steroidogenesis [6].
Overexpression of StAR can also decrease macrophage
lipidcontent,inﬂammatorystatusandarterialcholesterol
levels [7,8], and increase cholesterol efﬂux to apoAI
via a mechanism dependent upon mitochondrial sterol
27-hydroxylase (CYP27A1), LXR activation and in-
creases in ABCA1 mRNA and protein expression [9].
However, one ‘downside’ of StAR overexpression in
macrophages is the induction of lipogenesis [9], possibly
mediated by LXR-dependent increases in SREBP1c
expression, a problem also associated with non-sterol
LXR agonists.
The other member of the STARD1 subfamily
STARD3 [also known as MLN64 (metastatic lymph
node 64)] is a 54 kDa protein, co-ampliﬁed within
chromosome band 17q12, a region containing the potent
oncogene ERBB2 in human breast carcinoma [10–12].
STARD3 is a late endosomal protein with two distinct
conserved cholesterol-binding domains: a region of four
transmembrane helices with three short intervening
loops,calledtheMENTALdomain(MLN64N-terminal
domain), and the C-terminal ‘START’ domain [13]. The
MENTAL domain may maintain cholesterol at the late
endosomal membrane, prior to its shuttle to cytoplasmic
acceptor(s) via the START domain.
Our previous studies have shown that cholesterol
loading represses STARD3 expression, implicating this
protein in dysfunctional cholesterol pathologies [14]. In
the present study, we sought to establish a functional
role for this endosomal cholesterol trafﬁcking protein in
macrophage lipid homoeostasis, testing the hypothesis
that enhanced expression of STARD3 may be useful in
the prevention of foam cell formation.
MATERIALS AND METHODS
Materials
Tissue culture reagents were purchased from Lonza;
other reagents include pCMV.Script, and STARD4 and
STARD5 clones (Origene), STARD3 clone (Stratagene),
Amaxa monocyte/macrophage transfection reagent,
NuPAGE gels and buffers (Invitrogen), antibodies
(AbCAM), primersand ﬂuorescentprobes(Eurogentec),
and LDL (low-density lipoprotein) (Athens Research),
acetylatedasdescribedpreviously[14].Peripheralhuman
monocyte/macrophages were purchased from Lonza,
and human heart aorta RNA, derived from four to seven
human heart aortae, was purchased from Clontech.
Cellular studies
Human (THP-1) monocytes (ECACC 880812101) were
maintained in RPMI 1640 medium containing 10% (v/v)
FBS (fetal bovine serum), as described previously [14,15].
STARD3, STARD4, STARD5 and empty vector control
(pCMV; 0.5 μg of DNA) were delivered to THP-1
monocytes (107 cells) using an Amaxa Human Monocyte
Nucleofector® kit (VPA-1007). Transfection efﬁciency
using protocol Y001 (78.5%) was determined using
the proprietary pmaxGFP® vector provided by Amaxa
and ﬂow cytometric analysis of 50000 cells. Transfected
human THP-1 monocytes (1.5×106 cells/well) were
differentiated into macrophages by addition of 100 nM
PMA. Cellular lipids, RNA and cell protein lysates were
collected 72 h post-transfection. Macrophage foam cell
prevention experiments were initiated 48 h after transfec-
tion.Macrophages wereradiolabelledwith[3H]oleicacid
(1 μCi/ml; 10 μM) in the presence or absence of AcLDL
(acetylated LDL; 50 μg/ml) and with or without an
ACAT (acyl-CoA:cholesterol acyltransferase) inhibitor
(447C88; 10 μM) for 24 h. Wild-type macrophages were
incubated with progesterone (10 μM; 24 h) or U18666A
(25 μM; 24 h) to inhibit endosomal trafﬁcking, using
ethanol vehicle (<0.1%). Cellular viability was assessed
byconversionofMTT[3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide] into formazan. The
caspase-Glo® 3/7 assay system (Promega) was used to
detect apoptosis.
Lipid analyses
Flux of [3H]oleic acid (1 μCi/ml; 10 μM) into the cho-
lesterylesterpoolandof[14C]acetate(1μCi/ml)intocho-
lesterol, cholesteryl ester, fatty acid, triacylglycerol and
phospholipid pools were assessed by TLC, as described
previously[14,15].Efﬂuxof[3H]cholesterol(0.5 μCi/ml)
toapoA1(10 μg/ml)andHDL(high-densitylipoprotein;
10 μg/ml)weremeasuredasdescribedpreviously[13,15].
Mass of macrophage total cholesterol, triacylglycerol
and choline-containing phospholipids were measured
usingInﬁnityTM andPhospholipids-Bcolorimetricassays
(Alpha Labs) [14,15].
Gene and protein expression
Total RNA (Tri-Reagent; Sigma–Aldrich) was isolated
from macrophages and reverse-transcribed to cDNA
utilizing the MMLV (Moloney-murine-leukaemia virus)
reverse transcriptase (Bioline). Expression of STARD3,
STARD4, STARD5, APOE, ABCA1, ABCG1, ABCG4,
NR1H3 (encoding LXRα), SREBP1 and SREBP2
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Table 1 Sequence of primers and probes used to quantify mRNA by PCR
NR1H3 encodes LXRα.
Gene Forward primer Reverse primer Probe sequence
STARD3 5 -CCTGCCCCGGTACCTCAT-3  5 -GCGCTGTCGCAGGTGAA-3  5 -AGAGCCTCGCGGCCACCATGT-3 
STARD4 5 -AACATCAGACAGGCCTTCCA-3  5 -GAGAGCGGTGTGAGGTGCTT-3  5 -TAGCGCGCCGTAGCTTCCA-3 
STARD5 5 -GTGGACTTGGTGCTAGTCAAGAGA-3  5 -GACATAACGGATGCTCCACATG-3  5 -ATGTGGACCATCAGTTCCAACGCCA-3 
ABCA1 5 TGTCCAGTCCAGTAATGGTTCTGT-3  5 -AAGCGAGATATGGTCCGGATT-3  5 -ACACCTGGAGAGAAGCTTTCAACGAGACTAACC-3 
ABCG1 5 -ACGTGCCCTTTCAGATCAATGT-3  5 -GACGGCTGCGACGTCCATC-3  5 -CCCAGTGGCCTACTGCAGCATCGT-3 
ABCG4 5 -GGTTCATGTCCCACGTGGTT-3  5 -GCCGGTGTTGTTGAAGACCTT-3  5 -TCTACCTGCATATTGGCGACGATGCC-3 
APOE 5 -TGGGTCGCTTTTGGGATTAC-3  5 -CCATCAGCGCCCTCAGTT-3  5 -CTGCTCAGCTCCCAGGTCACCCA-3 
NR1H3 5 -GAACAACTGGGCATGATCGA-3  5 -AAGGAGCGCCGTTACACT-3  5 -AAGCTCGTCGCTGCCCAGCAA-3 
SREBP1 5 -GCTCCTCCATCAATGACAAAATC-3  5 -GCTTGAGTTTCTGGTTGCTGTGT-3  5 -AAGGCCATCGACTACATTCGCTTTCTGC-3 
SREBP2 5 -CGGTAATGATCACGCCAACA-3  5 -TGGTATATCAAAGGCTGCTGGAT-3  5 -TCAGCACCACTCCGCAGACGAGG-3 
GAPDH 5 -CACATGGCCTCCAAGGAGTAA-3  5 -TGAGGGTCTCTCTCTTCCTCTTGT-3  5 -cTGGACCACCAGCCCCAGCAAG-3 
mRNA, relative to the housekeeping gene GAPDH
(glyceraldehyde-3-phosphate dehydrogenase), was
performed by Q-PCR (quantitative real-time PCR),
using DNA engine Opticon 2 (MJ Research). PCRs
contained cDNA template, Q-PCR mix, molecular
biology grade water and 100 nM of each forward and
reverse primer, and ﬂuorescent probe [FAM (6-carbo-
xyﬂuorescein)/TAMRA (6-carboxytetramethylrhoda-
mine)]. Thermal cycling conditions were 15 min at 95◦C,
followed by 40 cycles of 15 s at 95◦Ca n d2 0sa t6 0 ◦C,
with status at 50◦C. Primers and probes are given in
Table 1. The comparative 2− Ct method was utilized for
quantiﬁcation of each gene relative to GAPDH mRNA.
MacrophagelysateswerecollectedinRIPAbufferplus
CompleteTM protease cocktail inhibitor (Roche). Protein
lysates (15–30 μg/well) were separated by SDS/PAGE
[NuPAGE; 10% (w/v) gels], transferred on to a PDVF
membraneandprobedusingrabbitanti-STARD3(1:1000
dilution) or anti-GAPDH (1:1000 dilution) polyclonal
antibodies, and a murine anti-ABCA1 monoclonal
antibody (1:1000 dilution). Detection was achieved using
appropriate secondary antibodies (1:1000 dilution) and
theECL(enhancedchemiluminescence)detectionsystem
[14]; densitometry was performed using Scion Image
software.
Statistical analyses
Values are means+ −S.E.M., and the number of inde-
pendent experiments is indicated in the Figure legends.
Signiﬁcant differences (P<0.05) were determined using
a Student’s t test or repeated measures ANOVA,
followed by Dunnett’s or Tukey–Kramer post-hoc tests,
asappropriate.*P<0.05,**P<0.01and***P<0.001for
comparisons are indicated.
RESULTS
Comparison of the endogenous expression of STARD3
mRNA, relative to housekeeping gene GAPDH,i n
Table 2 Endogenous gene expression of STARD3, relative
to GAPDH, in human (THP-1) monocytes and macrophages,
human peripheral blood monocyte/macrophages and human
heart aorta
Results are from three individual cDNA preparations, derived from 4×107 human
peripheral blood monocyte/macrophages (Lonza), the equivalent number of THP-1
monocytes and macrophages, and from a sample (50 μg) of four to seven pooled
human heart aortae (Clontech).
Expression of STARD3 mRNA
Source of RNA to GAPDH mRNA (×1000)
Human THP-1 monocytes 1.2+ −0.2
Human THP-1 macrophages 0.8+ −0.1
Human peripheral blood monocyte/macrophages 1.5+ −0.4
Human heart aorta 0.4+ −0.1
human THP-1 monocytes, THP-1 macrophages, human
peripheral blood monocyte/macrophages and human
heartaortaeisshowninTable2.Transientoverexpression
of STARD3 in human THP-1 monocyte/macrophages
increased mRNA levels by 87-fold (24 h; P<0.001),
20-fold (48 h; P<0.001) and 18-fold (72 h; P<0.05)
(Figure 1A), which translated into 2.2-fold (P<0.05)
increases in the levels of STARD3 protein after
72 h (Figure 2B) compared with the empty vector
control; all values were normalized to the level of
the housekeeping protein GAPDH. Cell viability was
not altered by STARD3 overexpression after 72 h
(25.4+ −2.4 μM formazan in the empty vector control
compared with 29.2+ −6.4 μM formazan in the STARD3-
overexpressing cells; n=6 independent experiments;
P=0.59), and the levels of macrophage caspase 3/7
activity did not change when STARD3 overexpression
was compared with the empty vector control (6971+ −270
arbitrary ﬂuorescent units in empty vector control
compared with 7632+ −1905 in STARD3-overexpressing
cells; n=3 independent experiments; P=0.509). No
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Figure 1 Overexpression studies: STARD3, STARD4 and STARD5
(A) Transient overexpression of STARD3 compared with empty vector control (24–72 h) in human THP-1 monocyte/macrophages overexpressing STARD3. (B) Effect of
STARD3 overexpression (72 h) on levels of SREBP2 and NR1H3 (LXRα) mRNA. Effect of overexpression of STARD4 (C) and STARD5 (D) on the gene expression of the
same transcription factors in (B). Values are means+ −S.E.M. of three independent experiments. *P <0.05, **P <0.01 and ***P <0.001 compared with the empty
vector control (pCMV).
Figure 2 Effects of STARD3 overexpression on macrophage lipid homoeostasis
(A) Levels of ABCA1, ABCG1, ABCG4 and APOE mRNA in monocyte/macrophages overexpressing STARD3 (72 h), compared with empty vector control, in three
independent experiments. (B) Levels of STARD3 and ABCA1 protein, compared with the housekeeping protein GAPDH, in THP-1 monocyte/macrophages (72 h). Blots are
representative of three independent experiments. The effect of STARD3 overexpression on (C) cholesterol efﬂux to apoAI (10 μg/ml) in ﬁve independent experiments,
and (D) biosynthesis of lipids from [14C]acetate (1 μCi/ml) in four independent experiments compared with empty vector controls,. Endosomal inhibitors U18666A
(25 μM) and/or progesterone (10 μM) are included as positive controls. All values are means+ −S.E.M. *P <0.05 and **P <0.01 compared with the empty vector
control (pCMV). In (D), signiﬁcant differences (P <0.05) from the control incubation for each lipid are indicated as a, free cholesterol; b, cholesteryl esters; c, fatty
acids; d, triacylglycerol; and e, phospholipids.
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changes in steady-state levels of mRNA encoding sterol-
responsivetranscriptionfactorsSREBP1(notdetectable),
SREBP2orNR1H3wereobserved,asjudgedbyQ-PCR
(Figure 1B). In comparison, overexpression of genes
encoding the cytosolic cholesterol transporters STARD4
(Figure 1c) and STARD5 (Figure 1D) exerted distinct
inﬂuences on gene expression of these transcription
factors:STARD4wasassociatedwithareduced(P<0.05)
expressionofSREBP2,whereasSTARD5overexpression
was associated with marked increases (P<0.05) in both
SREBP2 and NR1H3 mRNA levels.
Overexpression of STARD3 was associated with
signiﬁcant (P<0.05) increases (20.7-fold) in ABCA1
mRNA (Figure 2A) and protein (2.6-fold) (Figure 2B);
in contrast, no changes in ABCG1 and ABCG4
mRNA (Figure 2A) were observed between STARD3-
overexpressing macrophages and control cells following
normalization with GAPDH. These changes in gene
expression strongly predicted functional increases in
cholesterol efﬂux to apoAI, rather than to HDL,
followingSTARD3overexpression,andthisprovedtobe
correct,despiteasmallreductioningeneexpressionofthe
endogenous acceptor APOE.[ 3H]Cholesterol efﬂux to
apoAI (10 μg/ml; 24 h) was enhanced by 80% (P<0.05)
(Figure 2C), whereas efﬂux to HDL (10 μg/ml; 24 h) did
not change signiﬁcantly (5.27+ −0.58% of HDL-speciﬁc
efﬂuxinemptyvectorcontrolcomparedwith6.9+ −2.5%
of HDL-speciﬁc efﬂux in STARD3-overpexressing cells;
n=3; P=0.479). In contrast, inhibition of endosomal
trafﬁcking using progesterone (10 μM), blocked apoAI-
speciﬁc cholesterol efﬂux by 54% (n=3; P<0.01).
Decreases in the biosynthesis of cholesterol (25.5%;
P<0.05), cholesteryl ester (34.1%; P<0.01), fatty
acid (27.3%; P<0.05), triacylglycerol (41.9%; P<0.01)
and phospholipids (27.7%; P<0.05) from [14C]acetate
were observed in STARD3-overexpressing macrophages
(Figure 2D) compared with the empty vector control.
No change in total cholesterol (26.1+ −3.91 μg/mg
of protein in empty vector control compared with
27.2+ −3.15 μg/mgofproteininSTARD3-overexpressing
cells), triacylglycerol (83.7+ −10.9 μg/mg of protein in
empty vector control compared with 86.3+ −21.3 μg/mg
ofproteininSTARD3-overexpressingcells)orphosphol-
ipid mass (42.3+ −3.96 μg/mg of protein in empty vector
control compared with 47.1+ −8.31 μg/mg of protein
in STARD3-overexpressing cells) occurred over the
time scale investigated. Again, inhibition of endosomal
trafﬁcking using U18666A (25 μM) or progesterone
(10 μM) induced the opposite effect, increasing the
incorporation of [14C]acetate into each lipid pool
(P<0.05) (Figure 2D).
Importantly,whenSTARD3-overexpressingcellswere
challenged with AcLDL (50 μg/ml; 24 h), no signiﬁcant
increases in cholesterol esteriﬁcation occurred, as judged
by the incorporation of [3H]oleate into the cholesteryl
ester pool; in fact, a small but signiﬁcant (P<0.05)
Figure 3 Effect of STARD3 overexpression on macrophage
foam cell formation
Upper panel, incorporation of [3H]oleate (10 μM; 1 μCi/ml) into the cholesteryl
ester pool following incubation with AcLDL (50 μg/ml; 24 h) in the presence or
absence of the ACAT inhibitor 447C88 (10 μM) in wild-type cells, and in cells
transfected with either empty vector (EV) or STARD3. Values are means+ −S.E.M.
of four independent experiments. *P <0.05 and **P <0.01 compared with
controls; †P <0.05 compared with AcLDL alone; and ‡‡P <0.01 compared
with empty vector control treated with AcLDL. Lower panel, Oil Red O staining
in empty vector control (a and c) and STARD3-overexpressing cells (b and d)
incubated in the absence (a and b) or presence (c and d) of AcLDL (50 μg/ml;
24 h).
decrease was observed. In contrast, in untreated and
empty vector control cells, cholesterol esteriﬁcation
increased by approx. 2.2-fold (P<0.01) when treated
with AcLDL under the same conditions (Figure 3);
a change blocked by the ACAT inhibitor 447C88
(10 μM). Equally, an apparent reduction in intensity
of Oil Red O staining was observed in macrophages
overexpressing STARD3, compared with empty vector
control, after treatment with AcLDL (50 μg/ml; 24 h)
(Figure 3).
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DISCUSSION
The START family of lipid trafﬁcking may be involved
in non-vesicular cholesterol transport, regulating sterol-
responsive transcription factors, controlling the choles-
terol content of organelles, lipid rafts and membranes,
and storage of cholesterol as cytosolic droplets of
cholesterylester,althoughthemechanismsremainpoorly
understood at present.
Notably, our previous studies have demonstrated that
overexpression of distinct cholesterol and oxysterol-
binding proteins within the START family of lipid
trafﬁcking proteins, STARD1 (StAR) [9], STARD3,
STARD4 and STARD5, exert different effects on
gene expression of the sterol-responsive transcription
factors SREBP2 and LXRα. Overexpression of the
mitochondrial cholesterol transporter StAR is associated
with the induction of lipogenesis [9], possibly via
LXR-dependent induction of SREBP1c. Transient
overexpression of cytosolic STARD4 decreased SREBP2
mRNAlevelsbyapproximatelyhalf(Figure1C),whereas
overexpression of the gene encoding cytosolic STARD5
[16] protein resulted in marked increases in SREBP2
and NR1H3 mRNA levels compared with controls
(Figure 1D). Overexpression of STARD4 and STARD5
have been shown previously to activate an LXR reporter
plasmid in NIH-3T3 cells [17]. In contrast, STARD3
overexpression did not have an impact on either SREBP2
or NR1H3 mRNA levels (Figure 1B) and repressed
lipogenesis (Figure 2D). Although some of the observed
effects may be due to differences in gene expression
and translation levels, despite the delivery of equivalent
amounts of DNA to the same number of cells, they
may also reﬂect the efﬁciency and/or directionality of
the cellular cholesterol transport achieved [3,4].
Previously, we have speculated that STARD3 may
trafﬁc endosomally derived cholesterol to the ER (en-
doplasmic reticulum) and/or the plasma membrane [14];
even in the absence of lipoprotein-derived cholesterol,
cholesterol cycles between the plasma membrane and
endosomes[18].ThusSTARD3couldhelptoincreasethe
cholesterol content of the ER membrane, and retention
of SREBPs by the SCAP (SREBP2 cleavage-activating
protein)/Insig (insulin-induced gene)-1(-2) complex, in
agreement with the generalized repression of cholesterol,
fattyacidandtriacylglycerolbiosynthesisobservedinthe
present study. Cholesterol delivery to the ER might also
be expected to expand the substrate pool available for
esteriﬁcation by ACAT1 (SOAT1). Instead, expansion
of the cholesteryl [3H]oleate pool following exposure to
AcLDL was effectively blocked in cells overexpressing
STARD3.Oneexplanationforthisﬁndingisthatdelivery
of sterol to the ER was just sufﬁcient to sequester
SREBPs, but does not reach the threshold required to
activate ACAT. In turn, this must imply that the bulk
of the endosomal cholesterol trafﬁcked by STARD3 may
be efﬁciently directed elsewhere, perhaps to the plasma
membrane to facilitate cholesterol efﬂux, possibly via
vesicular transport facilitated by the Rab family of small
GTPases. Dissociation between cholesterol transport to
membrane-bound SREBP transcription factors and the
substrate pool available for cholesterol esteriﬁcation has
been reported previously [19,20]. Kristiana et al. [20]
observed clear differences in kinetics between endosomal
delivery of LDL-derived cholesterol to SREBPs and
ACAT in mutant CHO (Chinese-hamster ovary) cells
with cholesterol trafﬁcking defects [including NPC
(Niemann–Pick type C)], contending that different
cholesterol pools and/or transport pathways supply
SREBPs and ACAT within the ER.
Our present ﬁndings also agree well with deletion
studies of the START domain of STARD3 in mice in
vivo [21]. Although relatively modest changes in lipid
phenotype were observed, probably due to functional
redundancies within the START family of cholesterol
transfer proteins [21,22], signiﬁcant increases in hepatic
sterol ester were observed after feeding a high-fat diet,
together with the reduced conversion of cholesterol
into steroid hormones [21]. Use of a dominant-
negative mutant of STARD3 ( START-STARD3)
caused extensive cholesterol accumulation in CHO and
COS-7 cells, accompanied by inhibition of late
endosomal trafﬁcking, similar to the phenotype caused
by functional loss of NPC1/2 proteins [23]. Moreover,
in cholesterol-laden cells, STARD3 becomes trapped at
theperipheryofcholesterol-ladenlysosomes,reﬂectinga
loss of dynamic cholesterol movement [23], and deletion
of STARD3 is linked with disrupted actin-mediated
dynamics of late endocytic organelles, suggesting that
cholesterol binding or sensing by STARD3 in late
endosomal membranes may govern actin-dependent
fusion and degradative activity of that compartment [24].
Hepatic overexpression of STARD3 in vivo is associated
withincreasedconversionintobileacids[25],although,in
a separate study, apoptosis and hepatic toxicity were also
reported, probably resulting from the grossly elevated
and highly unphysiological levels of STARD3 utilized
[26]; such changes were not observed in the present
study.
Overexpression of STARD3 in the present study was
also associated with increased expression of ABCA1
mRNA and protein. The latter suggests that STARD3,
like NPC1, may facilitate trafﬁcking of endosomal
cholesterol and possibly ABCA1 protein through this
compartment to the plasma membrane, increasing pools
of membrane cholesterol and/or transporter available
for efﬂux to apoAI [27]. The mechanism(s) by which
STARD3 increases ABCA1 mRNA levels are less
obvious, as no induction of LXRα was observed in
our present experiments, and Npc1 inactivation reduces
Abca1 protein levels, but does not alter Abca1 mRNA
levels, in murine macrophages [28]. However, SREBPs
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Overexpression of STARD3 in human monocyte/macrophages 271
(1 and 2) can exert repressive effects on ABCA1 expres-
sion, decreasing cholesterol efﬂux [29,30]. Thus it is pos-
siblethatsequestrationofSREBPsattheER,assuggested
by the co-ordinated loss of lipid biosynthesis observed
in the present study, may relieve inhibition of ABCA1
gene expression and increase cholesterol efﬂux to apoAI.
Alternatively, STARD3 expression could alter levels of
ABCA1mRNAbychangingtheratiosofsaturatedtoun-
saturated fatty acids [31], or perhaps via its involvement
in actin-mediated dynamics of late endosomes [32] that
trigger changes in actin-dependent gene expression [33].
In conclusion, STARD3 overexpression may be useful
in limiting atherogenesis by up-regulating cholesterol
efﬂux mechanisms, reducing cholesterol synthesis and
inhibiting cholesterol esteriﬁcation. In vivo studies are
now needed to establish this contention, using murine
models of atheroma.
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